Takeda Pharmaceutical Co (TAK) said Monday that the European Medicines Agency has approved an additional subcutaneous administration option for hereditary angioedema drug TAKHZYRO, or lanadelumab.
The drug now comes in a 2 mL pre-filled pen for adolescent and adult patients, the company said.
Hereditary angioedema is a rare genetic disease that causes severe swelling in the body.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.